Display Settings:

Format

Send to:

Choose Destination

    Ann Gen Psychiatry. 2008 Dec 23;7:26.

    Aripiprazole augmentation in poor insight obsessive-compulsive disorder: a case report.

    Fornaro M, Gabrielli F, Mattei C, Vinciguerra V, Fornaro P.

    Dipartimento di Neuroscienze, Oftalmologia e Genetica (DINOG), Sezione di Psichiatria, Università di Genova, Italy. dott.fornaro@gmail.com.

    ABSTRACT: BACKGROUND: Obsessive-compulsive disorder is associated with a relevant impairment in social and interpersonal functioning and severe disability. This seems to be particularly true for the poor insight subtype, characterised by a lack of consciousness of illness and, consequently, compliance with treatment. Poor responsiveness to serotonergic drugs in poor insight obsessive-compulsive patients may also require an augmentation therapy with atypical antipsychotics. METHODS: We reviewed a case in which a patient with a long history of poor insight obsessive-compulsive disorder was treated with a high dosage of serotonin reuptake inhibitors. RESULTS: The treatment resulted in a poor outcome. This patient was therefore augmentated with aripiprazole. CONCLUSION: Doctors should consider aripiprazole as a possible augmentation strategy for serotonergic poor responder obsessive-compulsive patients, but further research on these subjects is needed.

    PMID: 19105842 [PubMed - in process]

    PMCID: 2621216

    Supplemental Content

    Click here to read Click here to read

    Patient drug information

    • Aripiprazole (Abilify®)

      Aripiprazole is used to treat the symptoms of schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions) in adults and teenagers 13 years of...